Yo Y, Moriguchi A, Higaki J, Nagano M, Nakano N, Kamide K, Yu H, Mikami H, Ogihara T
Department of Geriatric Medicine, Osaka University Medical School, Suita, Japan.
Nephron. 1997;76(4):466-71. doi: 10.1159/000190230.
We evaluated the renal effects of the new angiotensin II type 1 (AT ) receptor antagonist, HR 720, in the stroke-prone spontaneously hypertensive rat. Rats were treated with either vehicle, HR 720, MK-954 (a selective AT1 receptor antagonist) or enalapril for 6 weeks. Blood pressure was decreased to a similar extent by HR 720, MK-954 and enalapril (203 +/- 4, 202 +/- 5 and 190 +/- 4 vs. 247 +/- 4 mm Hg for control). Urinary protein secretion was also decreased (5.2 +/- 0.3, 5.3 +/- 0.2 and 5.5 +/- 0.6 vs. 25.2 +/- 4.6 mg/100g/24h). The glomerular hypertensive change was improved in each drug-treated group (2.0 +/- 0.2, 3.3 +/- 0.3 and 1.6 +/- 0.1 vs. 17.6 +/- 1.5%; p < 0.0001). These results show that, in addition to its antihypertensive effect, HR 720 has a beneficial effect on renal function.
我们在易患中风的自发性高血压大鼠中评估了新型1型血管紧张素II（AT）受体拮抗剂HR 720对肾脏的影响。大鼠分别接受赋形剂、HR 720、MK - 954（一种选择性AT1受体拮抗剂）或依那普利治疗6周。HR 720、MK - 954和依那普利使血压降低的程度相似（对照组为247±4 mmHg，用药组分别为203±4、202±5和190±4 mmHg）。尿蛋白分泌也减少了（分别为5.2±0.3、5.3±0.2和5.5±0.6，对照组为25.2±4.6 mg/100g/24h）。每个药物治疗组的肾小球高血压变化均得到改善（分别为2.0±0.2、3.3±0.3和1.6±0.1，对照组为17.6±1.5%；p<0.0001）。这些结果表明，HR 720除具有降压作用外，对肾功能也有有益影响。
